Board of Directors

ANDRÉ DE VILLERS, Director

Dr. André de Villers obtained his degree in medicine from Université de Montréal in 1973. Dr. de Villers has been closely involved in the emergence of the biotechnology sector in Quebec. From 1988 to 1993, he created and successfully managed several R&D venture capital companies, generating an investment totalling $250 million. In 1993, Dr. de Villers founded Theratechnologies and held successively the positions of President and Director of R&D, President and General Manager, and President and CEO and Vice Chairman of the Board until June 2004. During that period, Dr. de Villers has played a key role in the creation of Andromed, Ecopia BioSciences and Celmed BioSciences. Since January 2003, Dr. de Villers has been President & CEO of Celmed BioSciences, a private Canadian biopharmaceutical company. Celmed is a leader in the fields of oncology. Created in June 2001, Celmed develops therapies based on a photodynamic process for the treatment of haematological and immune diseases. From November 1999 to 2003, Dr. de Villers was also Chairman of the Biopharmaceutical Companies Committee of Canada's Research-Based Pharmaceutical Companies (Rx&D) and a member of its Board of Directors and carried out his mandate with success. He is presently a member of the Montreal International Life Sciences Committee and a member of the Board of H3 Pharma.

« Return to previous page